New MRI contrast agent could aid early stage cancer detection

For story suggestions or custom animation requests, contact [email protected] Visit http://archive.nextanimationstudio.com to view News Direct's complete archive of 3D news animations.

RESTRICTIONS: Broadcast: NO USE JAPAN, NO USE TAIWAN Digital: NO USE JAPAN, NO USE TAIWAN
Researchers claim that a new MRI contrast agent could be a "game changer" for the early detection of metastasizing cancers, especially liver cancer. This study was published in Science Advances on Feb. 5.

The paper focused on a form of eye cancer that can migrate to the liver during the early stages of metastasizing. Georgia State University's news release said that current tests often do not detect liver cancer before advanced stages.

The research team applied the metal element gadolinium to the contrast agent's protein. This allowed the MRI to accurately detect overexpression of receptors called CXCR4 in cancerous organs, even during early stage metastasis.

According to the paper, the contrast agent has been tested in mice, but the university says that the substance can identify multiple types of cancer cells and and the FDA is fast tracking human trials, which could begin in 18 months.

RUNDOWN SHOWS:
1. New MRI contrast agent may aid in early detection of metastasizing cancer
2. Current techniques does not reliably detect metastasizing cancer in early stages
3. Contrast agent utilize metal element gadolinium to identify receptor overexpression
4. Tests conducted with lab mice; human trials fast tracked and expected in 18 months

VOICEOVER (in English):
"Researchers claim that a new MRI contrast agent could be a 'game changer' for the early detection of metastasizing cancers, especially liver cancer. This study was published in Science Advances on Feb. 5."

"The paper focused on a form of eye cancer that can migrate to the liver during the early stages of metastasizing. Georgia State University's news release states that current tests often do not detect liver cancer before advanced stages."

"The research team applies the metal element gadolinium to the contrast agent's protein. This allows the MRI to accurately detect overexpression of receptors called CXCR4 in cancerous organs, even during early stage metastasis."

"According to the paper, the contrast agent has been tested in mice, but the university says that the substance can identify multiple types of cancer cells and the FDA is fast tracking human trials, which could begin in 18 months."

SOURCES: Science Advances, Georgia State University
https://advances.sciencemag.org/content/6/6/eaav7504
https://medicalxpress.com/news/2020-02-method-early-stage-cancer.html